{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T03:26:46Z","timestamp":1772681206647,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10147-022-02208-7","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T12:03:47Z","timestamp":1658405027000},"page":"1450-1458","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum"],"prefix":"10.1007","volume":"27","author":[{"given":"Takahiko","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8456-1248","authenticated-orcid":false,"given":"Atsuo","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Uetake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Suto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Moriwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotoshi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Ojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumasa","family":"Takii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisateru","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Saruta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyoshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Shiozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamichi","family":"Denda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"2208_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, Venook AP, Al-Hawary MM et al (2021) Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 19:329\u2013359","journal-title":"J Natl Compr Cancer Netw"},{"key":"2208_CR2","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27:1386\u20131422","journal-title":"Ann Oncol"},{"key":"2208_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44\u201370","journal-title":"Ann Oncol"},{"key":"2208_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-019-01485-z","volume":"25","author":"Y Hashiguchi","year":"2020","unstructured":"Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1\u201342","journal-title":"Int J Clin Oncol"},{"key":"2208_CR5","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"2208_CR6","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ et al (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA 317:2392\u20132401","journal-title":"JAMA"},{"key":"2208_CR7","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L et al (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426\u20131434","journal-title":"Lancet Oncol"},{"issue":"15 Suppl","key":"2208_CR8","doi-asserted-by":"publisher","first-page":"LBA3","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","volume":"32","author":"AP Venook","year":"2014","unstructured":"Venook AP, Niedzwiecki D, Lenz H-J et al (2014) CALGB\/SWOG80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 32(15 Suppl):LBA3","journal-title":"J Clin Oncol"},{"key":"2208_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","volume":"32","author":"F Rivera","year":"2017","unstructured":"Rivera F, Karthaus M, Hecht JR et al (2017) Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int J Colorectal Dis 32:1179\u20131190","journal-title":"Int J Colorectal Dis"},{"key":"2208_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S et al (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87\u201398","journal-title":"Eur J Cancer"},{"key":"2208_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY et al (2017) Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 28:1713\u20131729","journal-title":"Ann Oncol"},{"key":"2208_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","volume":"3","author":"F Petrelli","year":"2017","unstructured":"Petrelli F, Tomasello G, Borgonovo K et al (2017) Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 3:211\u2013219","journal-title":"JAMA Oncol"},{"key":"2208_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","volume":"3","author":"S Tejpar","year":"2017","unstructured":"Tejpar S, Stintzing S, Ciardiello F et al (2017) Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 3:194\u2013201","journal-title":"JAMA Oncol"},{"key":"2208_CR14","doi-asserted-by":"publisher","first-page":"e00065","DOI":"10.1136\/esmoopen-2019-000605","volume":"5","author":"XH You","year":"2020","unstructured":"You XH, Jiang YH, Fang Z et al (2020) Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open 5:e00065","journal-title":"ESMO Open"},{"key":"2208_CR15","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1200\/JCO.2009.26.6148","volume":"28","author":"C Cremolini","year":"2010","unstructured":"Cremolini C, Loupakis F, Ruzzo A et al (2010) Predictors of benefit in colorectal cancer treated with cetuximab: are we getting \u201cLost in TranslationAL\u201d? J Clin Oncol 28:e173\u2013e174 (author reply e175\u2013e176)","journal-title":"J Clin Oncol"},{"key":"2208_CR16","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.21037\/jgo.2018.07.01","volume":"9","author":"SH Hutajulu","year":"2018","unstructured":"Hutajulu SH, Paramita DK, Santoso J et al (2018) Correlation between vascular endothelial growth factor\u2014a expression and tumor location and invasion in patients with colorectal cancer. J Gastrointest Oncol 9:1099\u20131108","journal-title":"J Gastrointest Oncol"},{"key":"2208_CR17","first-page":"3865","volume":"28","author":"R Bendardaf","year":"2008","unstructured":"Bendardaf R, Buhmeida A, Hilska M et al (2008) VEGF-1 expression in colorectal cancer is associated with disease localization, stage, and long-term disease-specific survival. Anticancer Res 28:3865\u20133870","journal-title":"Anticancer Res"},{"key":"2208_CR18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","volume":"25","author":"E Missiaglia","year":"2014","unstructured":"Missiaglia E, Jacobs B, D\u2019Ario G et al (2014) Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 25:1995\u20132001","journal-title":"Ann Oncol"},{"key":"2208_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4251\/wjgo.v12.i4.405","volume":"12","author":"H Aggarwal","year":"2020","unstructured":"Aggarwal H, Sheffield KM, Li L et al (2020) Primary tumor location and survival in colorectal cancer: a retrospective cohort study. World J Gastrointest Oncol 12:405\u2013423","journal-title":"World J Gastrointest Oncol"},{"key":"2208_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00432-020-03167-0","volume":"146","author":"RP Marques","year":"2020","unstructured":"Marques RP, Godinho AR, Heudtlass P et al (2020) Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study. J Cancer Res Clin Oncol 146:1321\u20131334","journal-title":"J Cancer Res Clin Oncol"},{"key":"2208_CR21","doi-asserted-by":"publisher","first-page":"19815","DOI":"10.1038\/s41598-020-76756-1","volume":"10","author":"T Sagawa","year":"2020","unstructured":"Sagawa T, Sato Y, Hirakawa M et al (2020) Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab. Sci Rep 10:19815","journal-title":"Sci Rep"},{"key":"2208_CR22","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.7150\/jca.34550","volume":"10","author":"A Grassadonia","year":"2019","unstructured":"Grassadonia A, Di Marino P, Ficorella C et al (2019) Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. J Cancer 10:5926\u20135934","journal-title":"J Cancer"},{"key":"2208_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D et al (2013) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 14:29\u201337","journal-title":"Lancet Oncol"},{"key":"2208_CR24","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R et al (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499\u20133506","journal-title":"J Clin Oncol"},{"key":"2208_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Yoshino T, Cohn AL et al (2015) Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16:499\u2013508","journal-title":"Lancet Oncol"},{"key":"2208_CR26","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/bjc.2015.173","volume":"112","author":"A Rowland","year":"2015","unstructured":"Rowland A, Dias MM, Wiese MD et al (2015) Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 112:1888\u20131894","journal-title":"Br J Cancer"},{"key":"2208_CR27","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/cam4.2747","volume":"9","author":"LC Bylsma","year":"2020","unstructured":"Bylsma LC, Gillezeau C, Garawin TA et al (2020) Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med 9:1044\u20131057","journal-title":"Cancer Med"},{"key":"2208_CR28","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.clcc.2017.01.001","volume":"16","author":"T Yoshino","year":"2017","unstructured":"Yoshino T, Uetake H, Tsuchihara K et al (2017) Rationale for and design of the PARADIGM study: randomized phase III study of mFOLFOX6 plus bevacizumab or panitumumab in chemotherapy-na\u00efve patients with RAS (KRAS\/NRAS) wild-type, metastatic colorectal cancer. Clin Colorectal Cancer 16:158\u2013163","journal-title":"Clin Colorectal Cancer"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02208-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-022-02208-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-022-02208-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T03:31:41Z","timestamp":1661139101000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-022-02208-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["2208"],"URL":"https:\/\/doi.org\/10.1007\/s10147-022-02208-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"18 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT has received personal fees from Eli Lilly, personal fees from Taiho Pharmaceutical, grants and personal fees from Ono Pharmaceutical, personal fees from Chugai Pharma, grants and personal fees from Takeda, personal fees from Merck Serono, grants from Merck Sharp & Dohme, grants from Eisai, grants from Bayer Yakuhin, grants from Bristol Myers Squibb, all outside the submitted work. HY has received honoraria from Taiho Pharmaceutical, Chugai Pharma, Eli Lilly Japan, Merk Biopharma, Yakult Honsha, Bayer Yakuhin, and Takeda Pharmaceutical, all outside the submitted work. TE has received grants from MSD, Novartis, Ono, Astellas, Astellas Amgen Biopharma, BeiGene, Ignyta, Array BioPharma, Merck Serono, and Dainippon Sumitomo as well as honoraria from Chugai, all outside the submitted work. TT received personal fees from Daiichi Sankyo Co., Ltd. as well as grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., BeiGene Co., Ltd., and Ono Pharmaceutical Co., Ltd., all outside the submitted work. EB received research funding from Ono, Merck Sharp & Dohme, Eisai, Taiho, Bayer, Eli Lilly, Chugai, and Daichi-Sankyo as well as honoraria for lecture and advisory roles from Ono, Chugai, Taiho, Tsumura, Eli Lilly, Merck Sharp & Dohme, Sanofi, Miyarisan, Daiichi-Sankyo, AstraZeneca, Astellas, all outside the submitted work. TD received personal fees from Sysmex, Ono Pharmaceutical, and Sawai, all outside the submitted work. HU received research funding for his institution from Chugai and Takeda pharmaceutical companies, both outside the submitted work. TI, HS, HY, HU, MT, TS, HO, YT, AT, MG MSa, SO, KS, TF, MSh, KN, and YS declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}